Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) ... ACCESSWIRE
Market data is delayed by at least 15 minutes.
    Latest Story
    Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation
     ACCESSWIRE

    NEW YORK CITY, NY / ACCESS Newswire / October 22, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ:AQST). Investors who purchased Aquestive securities prior to June 16, 2025, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AQST.

    Aquestive Investigation Details

    The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in corporate wrongdoing.

    What's Next for Aquestive Investors?

    If you are aware of any facts relating to this investigation or purchased Aquestive shares, you can assist this investigation by visiting the firm's site: bgandg.com/AQST. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

    No Cost to Aquestive Investors

    We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

    Why Bronstein, Gewirtz & Grossman, LLC for Aquestive Securities Investigation?

    Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

    "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

    Follow us for updates on LinkedIn, X, Facebook, or Instagram.

    Contact Info

    Peretz Bronstein, Esq. or Nathan Miller
    Bronstein, Gewirtz & Grossman, LLC
    917-590-0911 | info@bgandg.com

    Attorney advertising.

    Prior results do not guarantee similar outcomes.

    SOURCE: Bronstein, Gewirtz & Grossman, LLC



    View the original press release on ACCESS Newswire

    Full Story →

    Headline News
    Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
    1:00p ET October 20 '26 ACCESSWIRE
    Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect
    1:00p ET October 18 '26 ACCESSWIRE
    Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation
    1:02p ET October 15 '26 ACCESSWIRE
    More News →
    Day  3.15%Week  5.82%Month  17.01%More Charting →
    October 23 '26. Markets Closed.
    Last $4.00
    Day change   3.15%$0.13
    Open $4.08
    Gap at open $0.05
    Previous close $4.13
    Trading volume 1,746,678
    10 Day avg vol. 2,545,115
    Shares out. 125.5Mil
    Market cap. $502.0Mil
    Trading activity Below Avg.
    Previous data from yesterday, October 22 '26.

    Historical Price Performance
    3 month   8.70% 
    6 month   2.44% 
    1 year   41.52% 
    2 year   27.01% 

    Earnings
    Previous 12m -$0.65
    Next 12m Estimate -$0.50
    P/E ratio --
    Revenue 54Mil

    Market data provided by News provided by